American Society of Hematology
|
Join Dr. Steve Rosen with special online reports direct from ASH 2009 in New Orleans. We're sure you'll find these updates from Dr. Rosen and the editorial team of Oncology NEWS International to be useful in your practice.
Check back here and watch for our e-mail update so you don't miss the best of ASH!
|
Four-drug regimen ups response, progression-free survival in older multiple myeloma patients
December 7, 2009
NEW ORLEANS—More is better, at least when it comes to treatments for multiple myeloma. Separate studies from a Spanish group and an Italian group showed that up-front use of four drugs improves durable responses and progression-free survival in elderly patients. Both studies also showed that a kinder, gentler weekly schedule of bortezomib (Velcade) instead of the standard twice-weekly schedule maintains efficacy and reduces toxicity.
Oral JAK2 inhibitor deflates symptoms in myelofibrosis disease
December 7, 2009
NEW ORLEANS—A new treatment for patients who are severely debilitated by myelofibrosis offers hope of a return to normal daily life. Preliminary studies with an oral drug INCB018424 that targets the Janus-activated kinase (JAK) 2 gene appears to markedly reduce the swelling of the spleen and sometimes the liver, which can, in turn, can change patients’ quality of life.
Scientific committee sessions showcase cutting edge research
December 3, 2009
NEW ORLEANS—The scientific program sessions are a unique offering at ASH, with an agenda that varies from the overall meeting. First, the speakers are invited to share their particular expertise with ASH attendees. Also, the abstracts are not peer-reviewed but are crafted specifically for the meeting.
|
|
|
